Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer. The RNA-targeted ...
"We will get to stage two, or phase two, and I'm very focused on that, and I think it's going to happen," Witkoff said Sunday on CBS News' "Face the Nation with Margaret Brennan." Witkoff said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback